Persistent racial/ethnic disparities in AIDS diagnosis rates among people who inject drugs in U.S. Metropolitan Areas, 1993-2007

Public Health Reports

Volumn 129, Issue 3, 2014, Pages 267-279

  Pouget, Enrique R ^a   West, Brooke S ^a   Tempalski, Barbara ^a   Cooper, Hannah L F ^b   Hall, H Irene ^c   Hu, Xiaohong ^c   Friedman, Samuel R ^a  

^a NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^b EMORY UNIVERSITY   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CONTROLLED STUDY; ETHNIC DIFFERENCE; HEALTH DISPARITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RACE DIFFERENCE; UNITED STATES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AFRICAN AMERICANS; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEALTHCARE DISPARITIES; HISPANIC AMERICANS; HUMANS; INCIDENCE; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES; URBAN POPULATION;

EID: 84899737847     PISSN: 00333549     EISSN: 14682877     Source Type: Journal    
DOI: 10.1177/003335491412900309     Document Type: Article

References (53)

1. Tempalski B, Pouget ER, Cleland CM, Brady JE, Cooper HL, Hall HI, et al. Trends in the population prevalence of people who inject drugs in US metropolitan areas 1992-2007. PLoS One 2013;8:e64789.
2. Centers for Disease Control and Prevention (US). HIV/AIDS surveillance supplemental report: cases of HIV infection and AIDS in the United States and dependent areas, by race/ethnicity, 2003-2007. Atlanta: CDC; 2009.
3. Wodak A, McLeod L. The role of harm reduction in controlling HIV among injecting drug users. AIDS 2008;22 Suppl 2:S81-92.
4. Vlahov D, Galai N, Safaeian M, Galea S, Kirk GD, Lucas GM, et al. Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol 2005;161:999-1012.
5. An Q, Prejean J, Hall HI. Racial disparity in U.S. diagnoses of acquired immune deficiency syndrome, 2000-2009. Am J Prev Med 2012;43:461-6.
6. Link BG, Phelan J. Social conditions as fundamental causes of disease. J Health Soc Behav 1995;Spec No:80-94.
7. Hogben M, Leichliter JS. Social determinants and sexually transmitted disease disparities. Sex Transm Dis 2008;35(12 Suppl):S13-8.
8. Rubin MS, Colen CG, Link BG. Examination of inequalities in HIV/AIDS mortality in the United States from a fundamental cause perspective. Am J Public Health 2010;100:1053-9.
9. CDC health disparities and inequalities report-United States, 2011. MMWR Morb Mortal Wkly Rep 2011;60(Suppl):1-124.
10. Racial/ethnic disparities in diagnoses of HIV/AIDS-33 states, 2001-2004. MMWR Morb Mortal Wkly Rep 2006;55(5):121-5.
11. Hall HI, Espinoza L, Benbow N, Hu YW. Epidemiology of HIV infection in large urban areas in the United States. PLoS One 2010;5:e12756.
12. An Q, Prejean J, McDavid Harrison K, Fang X. Association between community socioeconomic position and HIV diagnosis rate among adults and adolescents in the United States, 2005 to 2009. Am J Public Health 2013;103:120-6.
13. Pierce TG. Gen-X junkie: ethnographic research with young white heroin users in Washington, DC. Subst Use Misuse 1999;34:2095-114.
14. Office of Management and Budget (US). Standards for defining metropolitan and micropolitan statistical areas. Fed Reg 2000;65:8228-38.
15. Brady JE, Friedman SR, Cooper HL, Flom PL, Tempalski B, Gostnell K. Estimating the prevalence of injection drug users in the U.S. and in large U.S. metropolitan areas from 1992 to 2002. J Urban Health 2008;85:323-51.
16. Pouget ER, Friedman SR, Cleland CM, Tempalski B, Cooper HL. Estimates of the population prevalence of injection drug users among Hispanic residents of large U.S. metropolitan areas. J Urban Health 2012;89:527-64.
17. Cooper HL, Brady JE, Friedman SR, Tempalski B, Gostnell K, Flom PL. Estimating the prevalence of injection drug use among black and white adults in large U.S. metropolitan areas over time (1992-2002): estimation methods and prevalence trends. J Urban Health 2008;85:826-56.
18. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health 1996;86:642-54.
19. Friedman SR, Tempalski B, Cooper H, Perlis G, Keem M, Friedman R, et al. Estimating numbers of injecting drug users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injecting drug users. J Urban Health 2004;81:377-400.
20. Martin JA, Hamilton BE, Ventura SJ, Menacker F, Park MM, Sutton PD. Births: final data for 2001. Natl Vital Stat Rep 2002 Dec 18;51:1-103.
21. Kleinman JC, Kiely JL. Infant mortality. Healthy People 2000 Stat Notes 1991;1:1-10.
22. Hoover K, Bohm M, Keppel K. Measuring disparities in the incidence of sexually transmitted diseases. Sex Transm Dis 2008;35(12 Suppl):S40-4.
23. Keppel K, Pamuk E, Lynch J, Carter-Pokras O, Kim I, Mays V, et al. Methodological issues in measuring health disparities. Vital Health Stat 2 2005(141).
24. Braveman P. Health disparities and health equity: concepts and measurement. Annu Rev Public Health 2006;27:167-94.
25. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Kirmeyer S, et al. Births: final data for 2006. Natl Vital Stat Rep 2009 Jan 7;57:1-104.
26. Simoni JM, Huh D, Wilson IB, Shen J, Goggin K, Reynolds NR, et al. Racial/ethnic disparities in ART adherence in the United States: findings from the MACH14 study. J Acquir Immune Defic Syndr 2012;60:466-72.
27. Grigoryan A, Hall HI, Durant T, Wei X. Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US states, 1996-2004. PLoS One 2009;4:e4445.
28. Chen NE, Gallant JE, Page KR. A systematic review of HIV/AIDS survival and delayed diagnosis among Hispanics in the United States. J Immigr Minor Health 2011;14:65-81.
29. Lima VD, Nosyk B, Wood E, Kozai T, Zhang W, Chan K, et al. Assessing the effectiveness of antiretroviral regimens in cohort studies involving HIV-positive injection drug users. AIDS 2012;26:1491-500.
30. Werb D, Mills EJ, Montaner JS, Wood E. Risk of resistance to highly active antiretroviral therapy among HIV-positive injecting drug users: a meta-analysis. Lancet Infect Dis 2010;10:464-9.
31. Meditz AL, MaWhinney S, Allshouse A, Feser W, Markowitz M, Little S, et al. Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis 2011;203: 442-51.
32. Song R, Hall HI, Harrison KM, Sharpe TT, Lin LS, Dean HD. Identifying the impact of social determinants of health on disease rates using correlation analysis of area-based summary information. Public Health Rep 2011;126 Suppl 3:70-80.
33. Department of Health and Human Services (US). Report of the Secretary's Task Force on black and minority health. Washington: Government Printing Office (US); 1985.
34. Department of Health and Human Services (US). Healthy people 2000: national health promotion and disease prevention objectives-full report. DHHS Publication No. (PHS) 91-50212. Washington: HHS; 1991.
35. Department of Health and Human Services (US). Healthy people 2010: understanding and improving health. 2nd ed. Washington: Government Printing Office (US); 2000.
36. Department of Health and Human Services (US). Healthy people 2020: final review. Hyattsville (MD): HHS; 2011. Also available from: URL: http://www.cdc.gov/nchs/data/hpdata2010/hp2010_final_review.pdf [cited 2013 Aug 6].
37. Centers for Disease Control and Prevention (US). HIV prevention strategic plan through 2005. Atlanta: CDC; 2001.
38. Sharpe TT, McDavid Harrison K, Dean HD. Summary of CDC consultation to address social determinants of health for prevention of disparities in HIV/AIDS, viral hepatitis, sexually transmitted diseases, and tuberculosis. Public Health Rep 2010;125(Suppl 4):11-5.
39. Office of National AIDS Policy (US). National HIV/AIDS strategy for the United States. 2010 [cited 2013 Aug 6]. Available from: URL: http://www.whitehouse.gov/administration/eop/onap/nhas
40. Centers for Disease Control and Prevention (US). HIV strategic plan 2011 through 2015. Rockville (MD): Department of Health and Human Services (US); 2011.
41. Belani H, Chorba H, Fletcher F, Kroeger K, Lansky A, Leichliter J, et al. Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance from CDC and the U.S. Department of Health and Human Services. MMWR Recomm Rep 2012;61(RR-5):1-40.
42. Dolcini MM, Gandelman AA, Vogan SA, Kong C, Leak TN, King AJ, et al. Translating HIV interventions into practice: community-based organizations' experiences with the diffusion of effective behavioral interventions (DEBIs). Soc Sci Med 2010;71:1839-46.
43. Advancing HIV prevention: new strategies for a changing epidemic-United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52(15):329-32.
44. Ford CL, Airhihenbuwa CO. Critical race theory, race equity, and public health: toward antiracism praxis. Am J Public Health 2010;100 Suppl 1:S30-5.
45. Thomas JC, Thomas KK. Things ain't what they ought to be: social forces underlying racial disparities in rates of sexually transmitted diseases in a rural North Carolina county. Soc Sci Med 1999;49:1075-84.
46. Freudenberg N. Jails, prisons, and health of urban populations: a review of the impact of the correctional system on community health. J Urban Health 2001;78:214-35.
47. Centers for Disease Control and Prevention (US). Office of Minority Health and Health Equity. MHHE's guiding principle [cited 2013 Aug 6]. Available from: URL: http://www.cdc.gov/minorityhealth/about/OMHHE.pdf
48. Hemmige V, McFadden R, Cook S, Tang H, Schneider JA. HIV prevention interventions to reduce racial disparities in the United States: a systematic review. J Gen Intern Med 2012;27:1047-67.
49. Hall HI, McDavid K, Ling Q, Sloggett A. Determinants of progression to AIDS or death after HIV diagnosis, United States, 1996 to 2001. Ann Epidemiol 2006;16:824-33.
50. Lasry A, Sansom SL, Hicks KA, Uzunangelov V. Allocating HIV prevention funds in the United States: recommendations from an optimization model. PLoS One 2012;7:e37545.
51. Estrada AL. Health disparities among African-American and Hispanic drug injectors-HIV, AIDS, hepatitis B virus and hepatitis C virus: a review. AIDS 2005;19 Suppl 3:S47-52.
52. Broz D, Ouellet LJ. Racial and ethnic changes in heroin injection in the United States: implications for the HIV/AIDS epidemic. Drug Alcohol Depend 2008;94:221-33.
53. Friedman SR, Cooper HL, Osborne AH. Structural and social contexts of HIV risk among African Americans. Am J Public Health 2009;99:1002-8.